Insmed on Tuesday received Food and Drug Administration clearance for the first treatment for a chronic lung disease, opening the biotech up to what could be a multibillion-dollar product. Insmed will sell the daily pill, brensocatib, under the brand name Brinsupri for bronchiectasis. The approval comes after the treatment succeeded in one of last year’s most closely watched Phase 3 …
Read More »Insmed drug to treat lung disease bronchiectasis approved in U.S.
